



Jounce Therapeutics to Present at the J.P. Morgan Healthcare Conference

Cambridge, Mass. – January 6, 2015 – [Jounce Therapeutics, Inc.](#), a company focused on the discovery and development of novel cancer immunotherapies, today announced that Richard Murray, Ph.D., chief executive officer, will present a company overview at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 13 at 10 a.m. PT at the Westin St. Francis Hotel in San Francisco. The overview will include an update on the Jounce’s translational science platform, immune-oncology patient selection strategy and cancer immunotherapy portfolio overview.

About Jounce Therapeutics

Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce integrates translational science insights to select the right targets and patient populations with higher probability of success and achieve rapid proof-of-concept. The company is advancing programs that leverage contributions from our founders as well as knowledge acquired from Jounce’s Translational Science Platform to create a sustainable “discovery to human proof-of-concept” product engine with the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life. Founded by world leaders in tumor immunology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures. For more information, please visit www.jouncetx.com.

Media Contact:

Katie Engleman
Pure Communications, Inc.
910-509-3977
Katie@purecommunicationsinc.com

###